Logo Prima Biomed

Welcome to the Newsroom

12 April 2017

Prima BioMed receives A$492,144 Tax Refund from Australian Government

SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) (“Prima” or the
“Company”), is pleased to announce that it has received a A$492,144 cash rebate from the
Australian Federal Government’s R&D tax incentive program. The cash rebate provided in
respect of expenditure incurred on eligible R&D activities conducted in the 2016 fiscal year,
mainly related to the Company’s TACTI-mel trial, a Phase I clinical study in melanoma using its
lead compound IMP321, conducted in Australia.